Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
L2 is fine on etrade
InoLife Technologies Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, Sep 2, 2010 (GlobeNewswire via COMTEX) -- MicroStockProfit.com announces
an investment report featuring InoLife Technologies Inc. (INOL). The report
includes financial, comparative and investment analyses, and industry information
you need to know to make an educated investment decision.
The full report is available at: http://www.microstockprofit.com/lp/INOL
InoLife Technologies Inc. (INOL), formerly NexxNow Inc., is a development-stage
company. The Company is a service-based healthcare products development,
integration and marketing company, primarily focused upon products, services and
solutions. It operates two lines of businesses both in the medical field. Its
first line of business is the development of veterinary oncological treatments
(cancer in animals). Its second line of business is to provide deoxyribonucleic
acid (DNA) testing for paternity tests and to screen for certain genetic
diseases. It licenses the DNA test kits. The principal users of its products and
services include healthcare providers, including physicians, veterinarians,
hospitals and outpatient facilities, in addition to individuals with a direct
need for the solutions it provides. INOL is organized to address two specific,
but different, markets: the companion animal (dogs and cats) healthcare market
and the human healthcare market.
Message Board Search for INOL: http://www.boardcentral.com/boards/INOL
In the report, the analyst notes:
"The Company realized a net loss of $ 37,563 for the three months ended June 30,
2010. During the period from inception to June 30, 2010, INOL realized an
Accumulated Deficit of $1,130,890, primarily due to a total of $759,590 of Losses
Due to Recapitalization Expenses during the period from inception to June 30,
2010.
"INOL recently announced it will provide and market a proprietary metabolizing
test to physicians and practitioners to identify how a patient's genetic makeup
may affect the body's response to Plavix (colpidogrel)."
To read the entire report visit: http://www.microstockprofit.com/lp/INOL
See what investors are saying about INOL at http://www.stockhideout.com
Get breaking news on INOL at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider.
MicroStockProfit.com strives to provide a balanced view of many promising
small-cap companies that would otherwise fall under the radar of the typical Wall
Street investor. We provide investors with an excellent first step in their
research and due diligence by providing daily trading ideas, and consolidating
the public information available on them. For more information on
MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained
in any materials should be construed as a recommendation to buy or sell any
securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors,
LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest
in the mentioned company; nor have they received compensation of any kind for any
of the companies listed in this communication. Please read our report and visit
our Web site, MicroStockProfit.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, http://www.globenewswire.com
SOURCE: MicroStockProfit.com
CONTACT:MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
He is probably sick of all the people asking him, but that is who I spoke to.
What's the link that shows CEO owns 60mil?
that $30k buy caused a break out run. :)
Has not changed
this leg is probably where 10s will hit. :D
well over a million bucks has flowed through INOL today..lots of it thanks to DMG**** profits
haha yup someone painted 10 for $250
agree - 7's up any moment, might see an explosion of upticks like earlier. :)
yup lil shake n load now we're shootin up
sum1 is loadin up for the next run
yup, huge buys going through
InoLife Technologies, Inc. to Market a Plavix Metabolizing Test to
the Medical Industry
RALEIGH, NC -- (MARKETWIRE) -- 09/01/10 --
InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products
development, integration and marketing Company, announced today it will provide
and market a proprietary metabolizing test to physicians and practitioners to
identify how a patient's genetic makeup may affect the body's response to
Plavix (colpidogrel). The test will only be made available to physicians.
The Food and Drug Administration recently announced that Plavix must now
carry a so-called "black box" warning label after a landmark study revealed
that patients who were "non-responders" as a result of a genetic variation were
"3.58 times more likely to have a fatal stroke or myocardial infarction."
Plavix, an $8-billion-a-year drug and considered to be the second best
selling drug in the world, reduces the risk of heart attack, stroke, and
cardiovascular death in patients with cardiovascular disease by making
platelets less likely to form blood clots. Plavix does not have its
anti-platelet effects until it is metabolized into its active form by the liver
enzyme, CYP2C19.
"We determined that there are three critical problems that can lead to a
level of non-response to Plavix," said Dr. Frederic J. Vagnini, M.D., FACS, a
board certified cardiovascular surgeon who, after more than 20 years of
performing heart surgery, has turned his clinical practice to the prevention of
heart and related diseases. "First, in anyone an abnormality may be present
within a gene abbreviated as CYP2C19 (and other variants) which significantly
increases the risk of stroke or death due to clotting failure. Second, there
are different variants or mutations between ethnic groups; some studies have
indicated that one in three Caucasians and 40% of Asian of African-American
populations have this abnormality.
"Among clinicians there have been discussions centering on differing dosing
approaches. Perhaps the most important result of InoLife's DNA test is that
each patient will be able to have an individually tailored course of treatment
since some require longer periods on it," Vagnini stated.
InoLife Technologies feels that this is an important test for those who take
Plavix or who may need to take Plavix in the future. The Company is very
pleased that by addressing the black box warning, those who can be helped by
this medication will be.
InoLife's Plavix Metabolizing Test is only available to physicians and
medical professionals. It is not available for home use. Please ask your
physician.
(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals
Partnership.)
About InoLife Technologies, Inc Positioned for growth and success in a
burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily
focused on products, services and solutions that will enable state-of-the-art
healthcare for today and the future for a diverse base of customers and
end-users. The Company's mission is to identify, develop, integrate and bring
to market innovative healthcare-based products and services that provide timely
and practical solutions for both humans and companion animals. The primary
products and services that InoLife is currently addressing focuses upon those
specific products and services that provide key solutions through the
innovative use of specific DNA testing and Genetic analysis systems.
The principal customers of InoLife's products and services are healthcare
providers, physicians, practitioners, hospitals, outpatient facilities and
veterinarians. Emphasis is being placed on individuals with a direct need for
the DNA testing solutions. InoLife will be marketing and distributing its
proprietary products to a wide variety of customers through e-commerce, direct
sales, healthcare providers, distributors and retail sellers including
pharmacies, specialty retailers and drugstores.
Forward-Looking Statements Safe Harbor Statement under the Private
securities Litigation Reform Act of 1995: The statements contained herein,
which are not historical, are forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those expressed in the forward-looking statements including, but not
limited to, certain delays beyond the Company's control with respect to market
acceptance of new technologies, products and services, delays in testing and
evaluation of products and services, and other risks detailed from time to time
in the Company's filings with the Securities and Exchange Commission.
Contact: Henry Harrison IR Pro, 2.0, Inc. 407-862-5151
hharrison@insidewallstreet.com www.irprpro.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=osCpnGHqDrYg4OGMQohjpA%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
09-01-10 0845ET
08:45 090110
Yep. Couldn't agree more, will be a fun one to watch. thanks. :)
yes haha, fat fingered trade?
.06's back
DTRO promoted on StockHideout and Stockroach:
http://www.stockhideout.com
http://www.stockroach.com
Yup, things look like they are picking up? 35M in vol today
Me too. We've already seen more volume today than past PRs in the first few minutes.
** NEWS OUT 8/30 **
Deltron Blu Vu's Dr. Bozanic Completes Diving Expedition for Natural History
Museum & Uses Rebreather Technology to Collect Potential New Species
GARDEN GROVE, Calif., Aug 30, 2010 (BUSINESS WIRE) -- Deltron, Inc. (DTRO) is
pleased to announce that Dr. Jeffrey Bozanic, Vice President of Deltron's Blu Vu
division, has completed a diving expedition for the Natural History Museum of Los
Angeles and collected what appears to be a new species of brittle sea star from
the Pacific Ocean's easternmost coral atoll. Blu Vu designs and develops
closed-circuit rebreather technology, underwater life support systems that
recirculate breathing gases to enable deeper and longer dives. Using a
rebreather, Dr. Bozanic was able to collect marine specimens at 350 feet below
the surface, a depth far deeper than traditional scuba equipment would allow.
Founded in 2008, Deltron's Blu Vu division is led by internationally renowned
deep sea and cave diving expert Jeffrey Bozanic, Ph.D. Blu Vu designs and
develops proprietary closed-circuit rebreathers and components for deep sea oil &
gas exploration, mining, search and rescue, fire, building safety and hazardous
materials applications as well as for recreational diving.
Dr. Jeffrey Bozanic, Blu Vu's Vice President of Research and Development,
commented: "My team and I are proud to be a part of the collection and
identification of what could prove to be a new species of sea star on behalf of
the Natural History Museum. Using rebreather technology enabled me to dive at a
depth of 350 feet and stay underwater for 4 1/2 hours. Conventional scuba
equipment allows for a maximum depth of 130 feet and limits dive time to 45
minutes to an hour. At Blu Vu we believe demand for rebreathers in commercial and
recreational diving applications will continue to rise and are excited to forge
ahead in this growing field."
Clipperton Island is a small, ring-shaped coral atoll located 800 miles southwest
of Mexico in the Pacific Ocean. The uninhabited French island occupies
approximately 2 square miles and is home to a diverse range of marine species.
Dr. Bozanic and his team collected approximately 130 specimens containing as many
as 500 animals for the Natural History Museum of Los Angeles. The team collected
a rare, as-yet unnamed brittle sea star currently under review by the Museum's
nationally recognized Echinoderm Department.
About Deltron, Inc. (DTRO.OB)
Deltron acquires profitable businesses with strong management teams, substantial
revenue and established market positions. Wholly owned Elasco is a proven
innovator in product manufacturing with a 31-year operating history, diverse
customer base and vertically integrated manufacturing facility in Garden Grove,
California. Blu Vu, a division of Deltron, is a developer of proprietary closed
circuit rebreather technology and components that go beyond conventional scuba
systems to enable commercial and recreational divers to go deeper, stay
underwater longer and recover faster.
This Press Release may contain certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. DTRO has tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential" and similar expressions. These statements reflect DTRO's current
beliefs and are based upon information currently available to it.
Accordingly, such forward-looking statements involve known and unknown risks,
uncertainties and other factors which could cause DTRO's actual results,
performance or achievements to differ materially from those expressed in or
implied by such statements. DTRO undertakes no obligation to update or advise in
the event of any change, addition or alteration to the information catered in
this Press Release including such forward-looking statements.
SOURCE: Deltron, Inc.
Deltron, Inc.
Henry Larrucea
Investor Relations
714-908-5164
info@dtro.com
http://www.dtro.com
Copyright Business Wire 2010
Last 7 trades were buys, all right before the bell
100K
30K
80K
100K
50K
35K
30K
We've rebounded nicely today. Need another PR :)
I had that in my watchlist when it spiked to #1, but I luckily didn't invest. The next day or so, I noticed volume was essentially non-existent and took it off my list.
That suspension isn't nearly long enough, and obviously he probably will just use another handle. Looks like it was created on 7/29.
Ho hum.
He did TOMZ and DTRO?
Ok, I updated (created) an Ibox for Deltron. Click Show Ibox for the latest information.
I used gmail, sent another message, it went through. No bounce in my inbox.
to investor.relations@dtro.com
date Fri, Aug 27, 2010 at 9:28 AM
Nope, no bounce. I'll send it again, though, just to verify.
I emailed investor.relations too. Haven't received a response yet. Same?
I volunteered yesterday and am now a mod here
well the good news is we are no longer blacklisted. :) lets hope DTRO has some friday momo..
3rd it closed higher, the other two it did not, so that is what 3/3? So PR's have a 50% chance of driving this up or down. :)
That's not true according to my chart from the last couple of PR's, but because of the low float (56M) it does move all over the place...
8/25 (no pr)
Close: 0.008
Open: 0.0079
High: 0.011
Low: 0.006
Volume: 31,439,335
8/24 (PR released)
Close: 0.0045
Open: 0.0022
High: 0.006
Low: 0.0021
Volume: 1,574,660
8/23 (PR released)
Close: 0.0021
Open: 0.002
High: 0.0045
Low: 0.002
Volume: 907,755
8/13 (PR released, did close lower)
Close: 0.0046
Open: 0.0048
High: 0.0048
Low: 0.004
Volume: 645,683
Share Structure (as of yesterday, 8/25). I called the TA and this was what I was given:
OS: 554.5M
AS: 2B
Restricted: 180M
Issued: 123.9M
Float: 56.1M
Deltron has issued 7 PR's this month, all being very positive. Statistically, we should have another by the end of week, or early next week?
Deltron Secures International Patent Rights for Breathing Valve Technolgy (Aug 24)
Link: http://biz.yahoo.com/bw/100824/20100824006856.html?.v=1
DELTRON, INC. Financials (Aug 24)
Link: http://finance.yahoo.com/q/is?s=dtroe.ob
DELTRON, INC. Files SEC form 10-Q, Quarterly (Aug 23)
Link: http://biz.yahoo.com/e/100823/dtro.ob10-q.html
DELTRON, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Amendments to Articles of Inc (Aug 13)
Link: http://biz.yahoo.com/e/100813/dtro.ob8-k_a.html
Deltron Enables Leading U.S. Skateboard Manufacturer to Go Green (Aug 10)
Link: http://biz.yahoo.com/bw/100810/20100810005051.html?.v=1
Deltron Reports on Upswing in Sales and Customer Inquiries for Green Soy-Based Polyurethane Products (Wed, Aug 4)
Link: http://biz.yahoo.com/bw/100804/20100804005444.html?.v=1
Deltron Manufacturing Sees Rising Demand for Energy Efficient Building Insulation (Mon, Aug 2)
Link: http://biz.yahoo.com/bw/100802/20100802005585.html?.v=1
we really need an active mod here..hmm..
Called TA for share structure a few minutes ago. Here's what I was given:
OS: 554.5M
AS: 2B
Restricted: 180M
Issued: 123.9M
Float: 56.1M
10Q: We generated revenues from sales of our products in the amount of $1,1458,502 and $907,152 for the six months ended June 30, 2010 and 2009, respectively, and incurred $242,505 and $596,696 in selling general and administrative expenses for the six months ended June 30, 2010 and 2009, respectively.
wonder what DTRO will open at tomorrow?
here come the EOD buys